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Patients with Parkinson’s disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine
or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first
medication approved for management of PDP. How best to implement a switch to pimavanserin has not been clear, as
there are no controlled trials or case series in the literature to provide guidance. An abrupt switch may interrupt
partially effective treatment or potentially trigger rebound effects from antipsychotic withdrawal, whereas cross-taper
involves potential drug interactions. A panel of experts drew from published data, their experience treating PDP,
lessons from switching antipsychotic drugs in other populations, and the pharmacology of the relevant drugs, to
establish consensus recommendations. The panel concluded that patients with PDP can be safely and effectively
switched from atypical antipsychotics used off label in PDP to the recently approved pimavanserin by considering each
agent’s pharmacokinetics and pharmacodynamics, receptor interactions, and the clinical reason for switching (efficacy
or adverse events). Final recommendations are that such a switch should aim to maintain adequate 5-HT2A antagonism
during the switch, thus providing a stable transition so that efficacy is maintained. Specifically, the consensus
recommendation is to add pimavanserin at the full recommended daily dose (34mg) for 2–6 weeks in most patients
before beginning to taper and discontinue quetiapine or clozapine over several days to weeks. Further details are
provided for this recommendation, as well as for special clinical circumstances where switching may need to proceed
more rapidly.
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NbN-2 compliant keywords:
∙ pimavanserin: serotonin receptor inverse agonist/
antagonist (5-HT2A)
∙ clozapine: dopamine receptor antagonist (D2), ser-
otonin receptor antagonist (5-HT2), norepinephrine
receptor antagonist (α2)
∙ quetiapine: dopamine receptor antagonist (D2), ser-
otonin receptor antagonist (5-HT2), norepinephrine
reuptake inhibitor (metabolite)
Introduction
Parkinson’s disease psychosis (PDP) is an increasingly
recognized nonmotor aspect of Parkinson’s disease
(PD).1,2 Prior to 2016, recommendations for treating
PDP focused primarily on off-label use of clozapine and
quetiapine.3,4 Randomized, controlled trials demon-
strated efficacy for clozapine at low doses (6.25mg–
50.0mg/d) with limited adverse motor effects. Quetia-
pine failed to demonstrate clear efficacy in at least 4 of 5
clinical trials, but also had limited impact on motor
function, and was very commonly prescribed in PDP.5,6
The limited impact of these drugs on PD motor
symptoms may be attributed to the fact that both are
weak D2 receptor antagonists. Both are also antagonists
at serotonin 2A (5-HT2A) receptors, clozapine more
potently than quetiapine (see Table 1), which may
contribute to efficacy.7 Other antipsychotics that are
potent D2 antagonists or partial agonists generally
produce intolerable adverse motor effects and are not
recommended for PDP.8–10
In 2016, the US FDA approved the first drug for
treatment of psychotic symptoms in PDP.11 Pimavanserin
is a selective 5-HT2A receptor inverse agonist/antagonist
with no appreciable affinity for dopaminergic recep-
tors;12–14 it exerts clinically significant antipsychotic
effects without impact on motor symptoms.15–18 Since
the introduction of pimavanserin to the market, switch-
ing a PDP patient from a previous antipsychotic to
pimavanserin is a common clinical consideration, moti-
vated perhaps by lack of efficacy or side effect concerns
with the previous agent. However, the details of how to
implement such a switch have not been clear. An abrupt
switch involves stopping a drug that may have provided
partial benefit, potentially causing an interval of worsen-
ing psychosis or rebound insomnia before pimavanserin’s
TABLE 1. Receptor binding affinities for selected antipsychotic agents46





Pimavanserin - - + +++ - - - - -
Haloperidol ++++ - + + ++ ++ - - -
Clozapine ++ - + ++ +++ ++ ++ +++ ++++
Olanzapine +++ - + ++ + - + + + ++
Quetiapine ++ - + - - + + ++












































































+ weak binding affinity (100> Ki< 1000); + + moderate binding affinity (10> Ki< 100); + + + strong binding affinity (1> Ki< 10); + + ++ very strong binding affinity
(Ki< 1); Abbreviations: 5-HT= serotonin; α= adrenergic; D= dopamine; H= histamine; M=muscarinic. Ki (nM) values are derived from functional antagonist R-SAT™
assays (ACADIA, San Diego, CA, USA). “-“ denotes no response. Adapted from Hacksell et al. Neurochem Res 2014; 39: 2008–2017 and from data on file.
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expected onset of action. Cross tapering, on the other
hand, can raise concerns about drug interactions or QTc
prolongation due to the lack of data on combined therapy
with pimavanserin. In the absence of controlled trials
directly comparing these approaches, we here review
relevant principles to consider and provide expert
suggestions for how to switch patients from atypical
antipsychotics to pimavanserin.
Methods
A panel of 14 experts agreed to establish consensus
recommendations aimed at identifying optimal strategies
for switching from an off-label antipsychotic, especially
quetiapine or clozapine, to pimavanserin for patients
with PDP. Members of the group had expertise with PDP
(including movement disorders neurologists and neu-
ropsychiatrists) and with the receptor pharmacology of
antipsychotics, collectively treating thousands of
patients with PD and PDP, including more than 150
patients with pimavanserin. Twelve responded to a brief
survey about their PDP treatment experience and
preferences. This expert panel established the following
objectives:
∙ To present the pharmacology of atypical antipsycho-
tics as it relates to switching strategies
∙ To provide insights into current practice patterns and
potential challenges associated with switching
patients with PDP from atypical antipsychotics,
especially quetiapine or clozapine, to pimavanserin
∙ To seek consensus on recommendations for best
practices for how to switch patients to pimavanserin
This manuscript will review relevant antipsychotic
pharmacology, published recommendations on switch-
ing antipsychotics in primary psychiatric illnesses,19,20
and the pros and cons of various options from the
perspective of substantial collective clinical experience.
The manuscript was drafted by the authors, and all
agreed to the final content.
Box 1. Dosing Tips for Switching to Pimavanserin from Low Dose (<100mg) Quetiapine (see Figure 3)
∙ Add full dose (34 mg) pimavanserin to current low dose (up to 100 mg) quetiapine for 4 weeks.
∙ Allows primavanserin to reach steady state and the duration of treatment necessary to reach its delayed onset of therapeutic action.
∙ Then reduce quetiapine by 50% weekly until reaching 12.5 mg, then discontinue.
∙ If efficacy for PDP diminishes during quetiapine taper, can return to previous dose level and try tapering again in 1 week.
Box 2. Dosing Tips for Switching to Pimavanserin fromHighDose (>100mg)Quetiapine (see Figure 4)
∙ Add full dose (34 mg) pimavanserin to current high dose (>100 mg) quetiapine for 4 weeks.
∙ Allows pimavanserin to reach steady state and the duration of treatment necessary to reach its delayed onset of therapeutic action.
∙ Then reduce quetiapine by 25% weekly until reaching 12.5 mg, then discontinue.
∙ If efficacy for PDP diminishes during quetiapine taper, can return to previous dose level and try tapering again in 1 week.
Box 3. Dosing Tips for Switching to Pimavanserin from Low-Dose (<100mg) Clozapine (see Figure 5)
∙ Add full dose (34 mg) pimavanserin to continuing clozapine does for 6 weeks.
∙ Then reduce clozapine by 6.25 mg weekly until discontinued and in no event, not less than 4 weeks of tapering.
∙ If efficacy for PDP diminishes during clozapine taper, can return to previous dose level and try tapering again in 1 week.
∙ Recommend not removing patient from clozapine registry for a few months in case clozapine must be restarted.
Box 4. Dosing Tips for Switching to Pimavanserin fromHigh-Dose (≥100mg) Clozapine (see Figure 6)
∙ Add full dose (34 mg) pimavanserin to continuing clozapine does for 6 weeks.
∙ Then reduce clozapine by 6.25 mg weekly until discontinued and in no event, not less than 4 weeks of tapering.
∙ If efficacy for PDP diminishes during clozapine taper, can return to previous dose level and try tapering again in 1 week.
∙ Recommend not removing patient from clozapine registry for a few months in case clozapine must be restarted.
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PDP Diagnosis
The first step in treating PDP is to verify the diagnosis.
While definitions of PDP have differed over the years, a
National Institute of Neurological Disorders and Stroke–
National Institute of Mental Health working group
proposed diagnostic criteria for PDP in 2007 that require
at least 1 of the following: illusions, false sense of
presence, hallucinations, or delusions. These features
should not begin prior to the onset of PD motor
symptoms, and should be present for at least 1 month,
either as recurrent or continuous symptoms. Impor-
tantly, acute delirium and other medical, neurological,
or psychiatric causes should be excluded.2 Additionally,
clinical judgment should be used in considering the need
for treatment in patients with infrequent or non-
bothersome symptoms.
Treatment of PDP with Atypical Antipsychotics
Prior to 1990, medications for psychosis were limited to
antidopaminergic agents.21 However, administration of
first-generation, or typical, antipsychotic drugs resulted
in unacceptable exacerbation of motor symptoms due to
the blockade of dopamine receptors. Therefore, these
drugs and other strongly antidopaminergic treatments
are generally not used to treat PDP, a recommendation
supported by the Movement Disorder Society (MDS),22
American Geriatrics Society,23 and American Academy
of Neurology.24
Between 1993 and 2003, several second-generation,
or atypical, antipsychotic drugs were evaluated in
patients with PDP. Although these agents have been
approved as effective in the treatment of schizophrenia,
they vary greatly in their pharmacokinetic (PhK) and
pharmacodynamic (PhD) properties. For example,
receptor binding profiles include differing affinities
for an array of receptors types, including dopamine,
serotonin, acetylcholine, histamine, and adrenergic
receptors (Table 1). The differing PhK and PhD
properties in general, and the potency in binding
dopamine receptors in particular, lead to variable side
effect profiles. Clinical experience has shown that
drugs such as risperidone,25,26 olanzapine,27,28 aripi-
prazole,29 and ziprasidone30,31 may result in intoler-
able motor side effects for PD patients even at low
doses, and therefore are widely considered to be poor
choices for treatment of PDP. However, despite lacking
a US Food and Drug Administration (FDA) indication
for use in treating PDP, 2 of the atypical antipsychotics,
clozapine and quetiapine, have frequently been used to
manage the disorder.
Clozapine is an atypical antipsychotic drug with a
complex pharmacology (Table 1). It is a potent antago-
nist at the H1, 5-HT2B, 5-HT2C, and α1 receptors; a
potent inverse agonist at the 5-HT2A receptors; and a
relatively weak antagonist at the D2 receptors. Inverse
agonists are defined as drugs that, when bound to a
receptor, produce the opposite intracellular effect as the
endogenous ligand, even in the absence of the endogen-
ous ligand. Pivotal clinical studies showed that clozapine
improved PDP without substantially worsening parkin-
sonism.32–35 However, clozapine carries the risk of
neutropenia,36 which requires frequent blood testing.
The use of clozapine in PDP is also potentially further
constrained by other limiting side effects, such as
sedation, orthostatic hypotension, or anticholinergic
effects including constipation.
Quetiapine, another atypical antipsychotic medica-
tion that has been evaluated in PDP, exerts potent
antagonism at the H1 receptor and relatively weaker
binding at D2 and 5-HT2A receptors (Table 1). Quetia-
pine showed lesser antipsychotic benefit than clozapine
in some trials,37,38 but did not differ significantly in
another.35 However, in 4 of 5 randomized controlled
trials, quetiapine did not significantly reduce psychotic
symptoms compared with placebo when objectively
assessed using the Brief Psychotic Rating Scale.39–43
The fifth study specifically excluded patients with
delusions, and enrolled 16 patients, 5 of whom discon-
tinued prematurely (including 4 of the 8 patients
assigned to quetiapine). The treatment groups differed
significantly only on secondary outcome measures.39 In
terms of safety, reported side effects in these studies
included sedation, confusion, and orthostatic hypoten-
sion, which sometimes led to treatment discontinua-
tion.39–43 Among our panel, sedation was the quetiapine
side effect that most commonly motivated a switch to
pimavanserin (cited by all respondents), followed by
hypotension (cited by two-thirds). Nevertheless, many
experts continue to prescribe quetiapine in PDP, based
in part on their clinical experience.44 For instance, most
of our expert panel reported that pimavanserin was
their first-line medication for PDP, but one third chose
quetiapine.
The Evidence-Based Medicine Review from the MDS,
last published in 2012,22,24 concluded that clozapine is
efficacious for treating PDP with a safety risk that
requires specialty monitoring, while quetiapine has an
acceptable safety risk but may not be tolerated in this
population at doses needed for benefit. Due to the
monitoring requirements and safety risks of clozapine,
and the lack of convincing efficacy associated with
quetiapine, pimavanserin may be considered a first
option for the treatment of PDP. A recent evidence-
based review recommended pimavanserin and cloza-
pine as first-line agents,45 and the most recent
American Academy of Neurology classification recom-
mended pimavanserin and clozapine at level B, and
quetiapine at level C.11
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Treatment of PDP with Pimavanserin
In 2016, pimavanserin (NUPLAZID®, ACADIA Pharma-
ceuticals Inc.) became the first drug approved by the
FDA for the treatment of hallucinations and delusions
associated with PDP.13 Pimavanserin binds with high
affinity to 5-HT2A receptors as an inverse agonist, with a
5-fold lower affinity to 5-HT2C receptors, and has no
appreciable affinity for 5-HT2B, dopaminergic, muscari-
nic, histaminergic, or adrenergic receptors or for
calcium channels.12,46 An early phase 3 clinical trial
with subjects randomized to 0, 9, or 34mg/d showed
nonsignificant benefit for the highest dose (N= 298), as
did a trial with a maximum daily dose of 17mg (N= 123)
and a small, ascending dose, phase 2 study (https://
clinicaltrials.gov/ct2/results?term=pimavanserin).15,46
The pivotal clinical trial was a randomized, double-blind,
2-arm, phase 3 study in 199 patients. It showed that
pimavanserin 34mg daily was significantly better than
placebo at reducing frequency and/or severity of hallu-
cinations and delusions in patients with PDP asmeasured
using the Scale for the Assessment of Positive Symp-
toms–Parkinson’s Disease (SAPS-PD, p=0.0014) and
the SAPS Hallucinations and Delusions subscales
(p= 0.0011).16 Sleep quality, caregiver burden, and other
secondary outcome measures also significantly improved
with pimavanserin. Of course, treatment response
varies; in the pivotal clinical trial, 68% of pimavanserin
patients had a clinically meaningful response47 (vs. 43%
on placebo), 49% responded on the CGI-I (Clinical
Global Impressions–Improvement) scale (vs. 26% on
placebo), and partial response was typical (14% experi-
enced a complete remission vs. 1% on placebo).16,48 One
quarter of our panel reported concern for breakthrough
hallucinations or delusions as a reason for not switching
some PDP patients to pimavanserin.
Importantly, pimavanserin did not worsen motor
function compared with placebo, which is a major
concern when treating PDP. Serious adverse events were
uncommon in the clinical trials cited above, but the
pimavanserin label shares with other drugs for psychosis
a boxed warning of an increased risk of death in elderly
patients with dementia.
Initiating Pimavanserin in PDP Patients Not on an
Antipsychotic
When the decision has been made to start a patient on
pimavanserin, the recommended dose is 34mg by
mouth, once daily (Figure 1).13 Given the long half-life
of pimavanserin (approximately 57 hours), starting
34mg immediately will likely produce a gradual increase
in blood concentration over approximately 2 weeks. The
only exceptions to the use of the 34mg dose included in
the label are for patients who are taking strong inhibitors
of cytochrome P450 (CYP) 3A4, in which case a 10mg
daily dose is recommended, and in patients taking
CYP3A4 inducers, in whom “an increase in dosage may
be needed.”13,49 In the pivotal, randomized, placebo-
controlled, phase 3 trial, a decrease in psychotic
symptoms from baseline was evident at 2 weeks for
pimavanserin and placebo. Improvement in the pima-
vanserin arm separated from placebo beginning at
4 weeks, with further improvement at 6 weeks.16 The
improvement at 6 weeks was significant and clinically
meaningful.16 This time to onset of therapeutic action is
key to bear in mind when considering switching to
pimavanserin, especially when switching from drugs like
quetiapine or clozapine with much shorter half-lives.
Efficacy of pimavanserin was maintained at 10 weeks
during an open-label extension phase of the study.50
Therefore, a minimum of a 6-week trial period with the
34mg dose of pimavanserin is needed to fully assess
efficacy.
Pharmacologic Principles to Consider When
Switching PDP Patients from an Antipsychotic to
Pimavanserin
There are a number of factors that should be considered
to increase success in antipsychotic switches, including
PhK and PhD characteristics, receptor selectivity,
reasons for the switch (efficacy or adverse events), and
urgency of the switch. Although much of the data come
from studies in other populations, abrupt discontinua-
tion of antipsychotic drugs is known to cause both
withdrawal and rebound effects (Table 2). The appear-
ance of specific withdrawal symptoms depends on the
target receptor. For example, abrupt withdrawal from
antipsychotic drugs targeting dopamine D2 receptors, 5-
HT1A, and/or 5-HT2A receptors has been linked to
withdrawal dyskinesias and rebound psychosis (Table 2),
whereas abrupt withdrawal from drugs targeting hista-
mine H1 and muscarinic M1 receptors has been linked to
anxiety, agitation, and insomnia, and sometimes auto-
nomic symptoms such as sweating, tremor, diarrhea, and
other gastrointestinal symptoms (Table 2).7,20,51 The
potential for rebound and withdrawal phenomena is
greatest when the pre- and post-switch antipsychotics
differ considerably with regard to binding affinity for
specific receptors, as these effects typically involve
exposure of previously blocked receptors that are no
longer targeted by the post-switch antipsychotic (PhD
rebound). Differences in half-lives, time to steady
state, and metabolism between pre- and post-switch
antipsychotics (PhK rebound) may also contribute to
rebound and withdrawal symptoms (Table 2), espe-
cially if loss of 5-HT2A receptor occupancy occurs in
the transition between 2 drugs.51 Withdrawal effects in
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general may be less severe when discontinuing the
lower doses of quetiapine or clozapine typically
prescribed to patients with PDP than when discontinu-
ing the higher doses of antipsychotic drugs used in
patients with schizophrenia.
Potential Risk of Concomitant Therapy with
Antipsychotics and Pimavanserin During Cross Taper
Pimavanserin is generally well tolerated with no worsen-
ing of motor function.15–17 The safety profile of
pimavanserin is consistent with its receptor pharmacol-
ogy (Table 1) and differentiates this medication from
current antipsychotic drugs. Based on the tolerability
profile of pimavanserin, it is anticipated that there is a
low risk of exacerbating the side effects of other
antipsychotic medications when pimavanserin is admi-
nistered concurrently. However, as with all drug combi-
nations, clinicians should consider history of cardiac risk
factors and/or ECG data when pimavanserin is taken
concurrently with other antipsychotics, as each carries a
risk of modest (mean 5–10 msec) prolongation of the
QTc interval.
Recommendations: Switching to Pimavanserin in
Patients Currently Taking an Antipsychotic with
Suboptimal Efficacy and/or Tolerability
The goals of switching a patient with PDP from a current
antipsychotic medication, especially quetiapine or cloza-
pine, to pimavanserin are (1) to avoid dopamine D2
antagonism, (2) to maintain a stable level of 5-HT2A
antagonism during the transition so that efficacy is
maintained throughout the switch, and (3) to avoid
rebound effects whenever possible by monitoring the
pharmacology of the medications involved, usually by
slow down-titration of agents with anticholinergic and
antihistaminic actions, such as quetiapine and clozapine.
TABLE 2. Effects of blockade of receptors and potential side effects from withdrawal/rebound during switching
Receptor Effects of blockade Potential rebound/withdrawal effects
D2 Antipsychotic, antimanic, antiagression, EPS/akathisia, tardive
dyskinesia, increased prolactin
Psychosis, mania, agitation, akathisia, withdrawal dyskinesia
α1 Postural hypotension, dizziness, syncope Tachycardia, hypertension
α2 Antidepressant, increased alertness, increased blood pressure Hypotension
H1 Anxiolytic, sedation, sleep induction, weight gain, anti-EPS/akathisia Anxiety, agitation, insomnia, restlessness, EPS/akathisia
M1 (central) Memory, cognition, dry mouth, anti-EPS/akathisia Agitation, confusion, psychosis, anxiety, insomnia, sialorrhea, EPS/akathisia
M2−4 (peripheral) Blurred vision, constipation, urinary retention, tachycardia,
hypertension
Diarrhea, sweating, nausea, vomiting, bradycardia, hypotension, syncope
5-HT1A (partial agonism) Anxiolytic, antidepressant, anti-EPS/akathisia Anxiety, EPS/akathisia
5-HT2A Anti-EPS/akathisia, antipsychotic EPS/akathisia, psychosis

















FIGURE 1. Patients not currently taking antipsychotic medication. Start full dose of pimavanserin immediately.
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Several principles should be considered when initiat-
ing pimavanserin in patients with PDP who are already
taking an antipsychotic medication. Typical or atypical
antipsychotic drugs with a high risk of motor side
effects, such as haloperidol, risperidone, or olanzapine,
are not recommended for patients with PDP, and these
medications should be stopped as quickly as possible
(Figure 2). Motor worsening may persist for 30 days, and
often much longer, after these medications have been
discontinued. Clozapine and quetiapine (at doses
≤100mg) have a low propensity for worsening motor
symptoms of PD.
The nature, severity, and frequency of side effects and
the current dose should always be considered before
discontinuing medications. If one switches to pimavan-
serin because of the lack of efficacy with low-to-moderate
doses of quetiapine (≤100mg/day), for most cases
quetiapine may be tapered over 2–4 weeks starting
4–6 weeks after adding pimavanserin, with the goal of
minimizing rebound effects (eg, insomnia) and any loss
of antipsychotic benefit that might occur from abrupt
discontinuation of quetiapine (Box 1, Figure 3).7,51 The
duration of taper should depend on the current dose of
quetiapine; in cases of treatment with quetiapine at
>100 mg/day, a longer period of down-titration of the
quetiapine is suggested (Box 2, Figure 4). However, if a
patient is experiencing sedation during the day that
affects daily activities or increases the risk of falling,
reducing or eliminating the daytime dose of quetiapine
more abruptly may be considered. If, on the other hand, a
patient is deriving a nocturnal sleep benefit from
quetiapine due to sedation, removing the bedtime dose
may worsen sleep and lead to an increase in psychotic
symptoms. Given the low level of urgency for this type of
switching, the authors recommend avoiding 2 changes in
dosing at the same time (ie, increasing the new treatment
while decreasing the older treatment) in order to reduce
the risk of rebound agitation. Instead, it is recommended
to allow the pimavanserin being initiated to attain the
efficacy demonstrated at 4–6 weeks in controlled clinical
trials prior to a slow down-titration of quetiapine over a
few weeks. Persistent insomnia after withdrawal of
quetiapine may require adjustments to this plan.
When switching from concomitant clozapine, for
most cases, clozapine may be continued at the current
dose for 6 weeks with pimavanserin 34mg daily. At
6 weeks, total daily clozapine dose may be reduced by
6.25mg to 25mg weekly (Box 3, Figure 5), depending on
the starting dose (eg, reduce by 25mg if starting dose is
>100mg/day) and physician preference (Box 4,
Figure 6). Absolute neutrophil counts should be mon-
itored for 2 weeks after clozapine discontinuation (see













FIGURE 2. Patients currently taking contraindicated antipsychotic. Stop as






















FIGURE 3. Patients currently taking quetiapine (≤100 mg/day).
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patient may be continued in the clozapine registry for at
least 2 months so that the patient will not have to be re-
enrolled if clozapine is restarted.
As a general rule, if efficacy is reduced at any time
during the down-titration of quetiapine or clozapine,
return to the previous dose level and wait. Reduction can
be attempted again after 1 week, or if added benefit of
the combined therapy is clear, the patient may need to
continue both medications.
Conclusions
Antipsychotic drugs are commonly used by clinicians to
treat patients with PDP. The goal of this review was to
summarize the challenges of switching antipsychotic
drugs in patients with PDP, and to provide consensus
guidance on approaches to switching from atypical
antipsychotics to pimavanserin. Understanding the
receptor binding and safety profile of antipsychotics










































FIGURE 5. Patients currently taking clozapine (≤100mg/day).
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with PDP. In the absence of controlled clinical trials
aimed at evaluating the optimal conditions for switching,
a challenge for clinicians is to determine the type of
discontinuation (abrupt vs tapered) for the current
antipsychotic drug and the timing and starting dose of
the newmedication in order tomaintain optimal receptor
occupancy and limit the risks of rebound effects. Most
commonly, according to clinical experience, when
switching from quetiapine to pimavanserin, reducing



































































Maintenance therapy on pimavanserin
FIGURE 7. Algorithm for initiating pimavanserin.
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work may cause the patient to deteriorate during the
switch. This can be avoided by waiting to taper quetiapine
for 4 to 6 weeks after starting pimavanserin. The overall
algorithm suggested as guidance for switching to pima-
vanserin for PDP patients taking an antipsychotic is
summarized in Figure 7. Ultimately, the optimal methods
for switching will depend not only on the pharmacology
and safety of antipsychotic drugs, but also on individual
patient profiles (ie, a precision medicine approach).
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